Diego A. Díaz García/X
May 6, 2025, 11:07
Diego A. Díaz García: HER3 – From Understudy to Key Target
Diego A. Díaz García, Medical Oncologist , CEO and Founder at CánCare, shared an article on X:
“HER3: from understudy to key target.
Once overlooked, HER3 is now gaining ground in cancer therapy. New strategies including ADCs & bispecifics show promise—like FDA-approved Zenocutuzumab for NRG1+ NSCLC & pancreatic cancer.
This article offers an essential overview of:
- HER3 biology, mutations, and expression in tumors.
- Its role in therapy resistance and immune interactions.
- Emerging HER3-directed therapies and their potential across cancer types.”
Emerging importance of HER3 in tumorigenesis and cancer therapy.
Authors: Joan T. Garrett, Salomon Tendler, Wasim Feroz, Mary Kate Kilroy, Helena Yu.
You can read the Full Article on Journal of Nature Reviews Clinical Oncology.
More posts featuring Diego A. Díaz García.
ADCs
CánCare
cancer
cancer therapy
Diego A. Díaz García
FDA
fight against cancer
Global fight against cancer
Helena Yu
HER3
Joan T. Garrett
Key Target
Mary Kate Kilroy
NRG1
NSCLC
OncoDaily
Oncology
Pancreatic Cancer
Salomon Tendler
therapy resistance
tumorigenesis
Understudy
Wasim Feroz
zenocutuzumab
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 6, 2025, 11:07
May 6, 2025, 10:59
May 6, 2025, 10:56
May 6, 2025, 10:48
May 6, 2025, 10:47
May 6, 2025, 10:46
May 6, 2025, 10:37